Paxil Injuries



Baum Hedlund client testifies about Paxil to the FDA

Baum Hedlund client testifies about Paxil to the FDA

Click Here to View Her Testimony


Baum, Hedlund, Aristei & Goldman's drug department litigates pharmaceutical drug product liability lawsuits.  They have represented thousands of victims of drug-induced injury and death for more than 20 years. Baum Hedlund has extensive experience in litigating personal injury, wrongful death and consumer class action cases against major drug companies and has been litigating a number of different types of cases against GlaxoSmithKline (GSK), the maker of Paxil, for many years.  Baum Hedlund has the longest track-record of handling SSRI antidepressant litigation.

Baum Hedlund’s Extensive Experience re: Paxil

Paxil Suicide and Suicide Attempt Cases

Paxil Consumer Class Action Lawsuits

Baum Hedlund’s Extensive Experience Litigating Injury and Death Cases Against GSK

Our law firm filed its first Paxil injury lawsuit against GSK in 2001. In that litigation, Baum Hedlund was appointed lead counsel in charge of the Plaintiffs’ Steering Committee for the Paxil Products Liability Litigation (Multidistrict Litigation MDL-1574) in which Baum Hedlund represented more than 3,000 people across the United States in personal injury cases against GSK.

Return to Top


Baum Hedlund lawyer sets the record straight about “new working paper” on antidepressants and teen suicide and responds to Reason Magazine’s recycled and unwarranted conclusions about the rise in teen suicides, declining grades, etc., by pharma-funded academics which have been debunked by other scientists and by the authors themselves.

Paxil Suicide and Suicide Attempt Cases

The firm has been litigating Paxil suicide and suicide attempt cases for the past several years and has a number of cases pending in courts across the United States. Baum Hedlund has collected hundreds of thousands of pages of internal GSK documents and conducted dozens of depositions of GSK executives, employees, physicians, researchers and academics. As a result, we know how GSK operates, we know its tactics, the key players and how to get the evidence needed to effectively litigate cases against GSK. 

Key preemption win in Paxil suicide case.We have seen the harm antidepressants can cause and the extent to which drug companies will go to protect their enormously profitable drugs and we and our clients have testified about this to the FDA. Baum Hedlund has accumulated a considerable body of evidence demonstrating that Paxil is associated with an increased risk of suicidality in all age groups, not just children and young adults, and that GSK was aware of the risk and yet chose not to warn the public of this serious risk. Instead, GSK over promoted the benefits of the drug while downplaying the risks.

On October 15, 2004, the FDA asked antidepressant manufacturers to add a black box warning to their labels to alert health care providers to an increased risk of suicidality caused by antidepressants in children and adolescents.  On May 2, 2007, the FDA announced that it had asked antidepressant manufacturers to expand the current black box warnings concerning the increased risk of suicidality in children and adolescents to include young adults, but only ages 18 to 24.  Based on our own 18-year investigation into the harmful side effects of antidepressants, we believe this warning should include people of all ages.  

The Truth About Antidepressant-Induced Suicide

To learn more about the adverse reactions associated with Paxil,
please visit www.a-paxil-lawyer-source.com.


For more information and resources concerning antidepressants, visit
antidepressantadversereactions.com.



Return to Top


Consumer Class Action Lawsuits

Since 2004, Baum Hedlund has been litigating Private Attorney General consumer fraud class action lawsuits against GSK on behalf of individuals and entities (insurance companies, state medical welfare agencies)  in California, Florida, Massachusetts, Nevada, New Jersey, Pennsylvania, Texas and Washington. 

The cases are based on internal GSK documents showing that GSK falsely promoted Paxil as an effective medication for children and adolescents despite internal communications acknowledging that Paxil’s pediatric depression clinical trials failed to out-perform sugar pills, yet had higher suicidality rates than sugar pills. Notwithstanding, GSK promoted Paxil as being “remarkably safe and effective” for depressed children. A settlement was reached in April 2007 wherein GSK agreed to reimburse parents for all of the money they paid for their children’s Paxil prescriptions. To learn more about this settlement please visit
http://www.baumhedlundlaw.com/bhl2_press/paxil_pediatric_class_action.php.

Baum Hedlund’s consumer fraud cases on behalf of the entities class (state agencies, insurance companies) will be continuing in cases filed in Minnesota and California with insurance companies as class representatives to recover funds they paid for pediatric Paxil prescriptions.

Return to Top